InnDura Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $3.2M

Overview

InnDura Therapeutics is an early-stage biotech focused on next-generation cell and gene therapies using in vivo mRNA delivery. Its core technology integrates targeted LNPs with the proprietary EVE16™ platform to reprogram immune cells directly within the patient's body, aiming for more effective and accessible immunotherapies. The company is pre-clinical and pre-revenue, operating as a private entity. Its location in Cambridge provides access to top-tier talent, capital, and research collaborators, positioning it to advance its platform toward clinical development.

OncologyImmunology

Technology Platform

Proprietary EVE16™ platform combined with targeted lipid nanoparticles (LNPs) for in vivo delivery of mRNA to reprogram a patient's own cells into therapeutic polytypic cell therapies.

Funding History

1

Total raised:$3.2M

Seed$3.2MUndisclosedJan 15, 2023

Opportunities

The platform targets a major limitation of current cell therapies by enabling in vivo, off-the-shelf generation of therapeutic cells, which could drastically reduce cost, complexity, and time-to-treatment.

Its modular mRNA/LNP approach allows for rapid iteration and potential application across multiple disease areas, creating a broad pipeline opportunity.

Risk Factors

The core technology of in vivo cell engineering is unproven and faces significant scientific hurdles related to delivery efficiency, specificity, and safety.

As a pre-revenue, pre-clinical company, it is highly dependent on raising capital in a competitive funding environment and faces intense competition from other firms pursuing similar approaches.

Competitive Landscape

InnDura competes in the rapidly evolving 'in vivo cell therapy' space with companies like Capstan Therapeutics, Cartesian Therapeutics, and Umoja Biopharma, as well as large mRNA players (e.g., Moderna, BioNTech) exploring similar concepts. Success will depend on demonstrating superior targeting, efficacy, or safety profiles compared to these well-funded competitors.

More companies in Cell & Gene Therapy →More companies in United States →